Back to top
more

Amneal Pharmaceuticals (AMRX)

(Delayed Data from NSDQ)

$8.49 USD

8.49
922,984

+0.02 (0.24%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $8.48 -0.01 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?

by Zacks Equity Research

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Benjamin Rains headshot

How to Find Great Cheap Stocks Under $10 to Buy in October

by Benjamin Rains

On top of their cheap price tags, Wall Street analysts are high on all of these stocks and their improving earnings outlooks earn them strong Zacks Ranks.

Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Amneal Pharmaceuticals (AMRX) and Astrazeneca (AZN) have performed compared to their sector so far this year.

Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?

by Zacks Equity Research

Relay Therapeutics (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates

by Zacks Equity Research

AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.

Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

by Zacks Equity Research

Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy as Innovation Reaches Peak

by Kinjel Shah

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Sensus Healthcare, Inc. (SRTS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 14.29% and 6.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 12.50% and 99.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q2 Earnings

by Zacks Equity Research

Get a deeper insight into the potential performance of Amneal (AMRX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zoetis (ZTS) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 4.70% and 2.53%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales

by Zacks Equity Research

Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales.

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amneal Pharmaceuticals (AMRX) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Amneal Pharmaceuticals (AMRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?

by Zacks Equity Research

Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Amneal (AMRX) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall

by Zacks Equity Research

Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.

Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 55.56% and 5.80%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?